MedTrace Logo

Zanubrutinib in Patients With Waldenström's Macroglobulinemia, Chronic Lymphocytic Leukemia, Marginal Zone Lymphoma and Follicular Lymphoma

NCT05326308 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 705

Last updated 2025-09-23

No results posted yet for this study

Summary

The objective of this NIS is to evaluate medical resource utilization, where data is rare in all cohorts, patient's QoL and effectiveness of zanubrutinib treatment in adult patients with WM, CLL, MZL and FL in a real-world setting.

Conditions

Interventions

DRUG

Zanubrutinib

according to the Summary of Product Characteristics (SmPC).

DRUG

Obinutuzumab

according to the Summary of Product Characteristics (SmPC).

Sponsors & Collaborators

  • BeOne Medicines I GmbH Switzerland

    collaborator UNKNOWN

  • iOMEDICO AG

    lead INDUSTRY

Principal Investigators

  • Jens Kisro, Dr. · Lübecker Onkologische Schwerpunktpraxis

  • Richard Greil, Prof. · Universitätsklinikum Salzburg, Klinik für Innere Medizin III

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-04-26
Primary Completion
2028-08-31
Completion
2028-08-31

Countries

  • Austria
  • Germany

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05326308 on ClinicalTrials.gov